Quote | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
Last: | $0.0082 |
---|---|
Change Percent: | -26.26% |
Open: | $0.0125 |
Close: | $0.0082 |
High: | $0.0125 |
Low: | $0.0067 |
Volume: | 30,102 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
Message Board Posts | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 Company Name:
ATNFW Stock Symbol:
NASDAQ Market:
MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in i...